Mexate-aq

   
Google
 
Web NewDrugInformation.com

Mexate-aq


Drug - Mexate-aq
The trade name of the product as shown on the labeling.

Dosage - INJECTABLE; INJECTION
The product dosage form and route separated by a semi-colon.

Active Ingredient(s) - Methotrexate Sodium
Multiple ingredients are in alphabetical order.

Strength - EQ 25MG BASE/ML
The potency of the active ingredient(s), Methotrexate Sodium. May repeat for multiple part products.

Applicant - BRISTOL MYERS
The firm name holding legal responsibility for Mexate-aq. The firm name is condensed to a maximum twenty character unique string.

New Drug Application (NDA) Number - 088760
The FDA assigned number to Mexate-aq. Format is nnnnnn.

Product Number - 001
The FDA assigned number to identify Mexate-aq. Each strength is a separate product. May repeat for multiple part products. Format is nnn.

Therapeutic Equivalence (TE) Code -
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.

Approval Date - Feb 14, 1985
The date Mexate-aq was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".

Reference Listed Drug (RLD) - No
The pioneer or innovator of Mexate-aq. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.

Type - DISCN
The group or category of approved drugs Mexate-aq is in. Format is RX, OTC, DISCN.

Applicant Full Name - Bristol Myers Co
The full name of the firm holding legal responsibility for the new application of Mexate-aq.

Mexate-aq